Zobrazeno 1 - 10
of 255
pro vyhledávání: '"Lisa M McShane"'
Autor:
Chen Zhao, Li Chen, Albrecht Stenzinger, Yali Li, Naiyer Rizvi, Jeff Allen, Matthew Hellmann, Diana M Merino, Lisa M McShane, David Fabrizio, Vincent Funari, Shu-Jen Chen, James R White, Paul Wenz, Jonathan Baden, J Carl Barrett, Ruchi Chaudhary, Wangjuh (Sting) Chen, Jen-Hao Cheng, Dinesh Cyanam, Jennifer S Dickey, Vikas Gupta, Elena Helman, Joerg Maas, Arnaud Papin, Rajesh Patidar, Katie J Quinn, Hongseok Tae, Christine Ward, Mingchao Xie, Ahmet Zehir, Manfred Dietel, Mark Stewart
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Background Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase of interrogated genomic sequence, demonstrates predictive biomarker potential for the identification of patients with cancer most likely to respond to i
Externí odkaz:
https://doaj.org/article/e8663839837544db9634250292b948f0
Autor:
Mariam M. Konaté, Julia Krushkal, Ming-Chung Li, Li Chen, Yuri Kotliarov, Alida Palmisano, Rini Pauly, Qian Xie, P. Mickey Williams, Lisa M. McShane, Yingdong Zhao
Publikováno v:
Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-14 (2024)
Abstract Background With poor prognosis and high mortality, pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies. Standard of care therapies for PDAC have included gemcitabine for the past three decades, although resistance
Externí odkaz:
https://doaj.org/article/8450290fb1bd45a187afecbd4534732f
Autor:
Danielle Mercatante Carrick, Michele G Mehaffey, Michael C Sachs, Sean Altekruse, Corinne Camalier, Rodrigo Chuaqui, Wendy Cozen, Biswajit Das, Brenda Y Hernandez, Chih-Jian Lih, Charles F Lynch, Hala Makhlouf, Paul McGregor, Lisa M McShane, JoyAnn Phillips Rohan, William D Walsh, Paul M Williams, Elizabeth M Gillanders, Leah E Mechanic, Sheri D Schully
Publikováno v:
PLoS ONE, Vol 10, Iss 7, p e0127353 (2015)
Next Generation Sequencing (NGS) technologies are used to detect somatic mutations in tumors and study germ line variation. Most NGS studies use DNA isolated from whole blood or fresh frozen tissue. However, formalin-fixed paraffin-embedded (FFPE) ti
Externí odkaz:
https://doaj.org/article/66eecb3a1c8949b0ba95630dac227961
Autor:
Julia Krushkal, Yingdong Zhao, Kyle Roney, Weimin Zhu, Alan Brooks, Deborah Wilsker, Ralph E. Parchment, Lisa M. McShane, James H. Doroshow
Publikováno v:
Epigenetics, Vol 19, Iss 1 (2024)
ABSTRACTHistone deacetylases (HDACs) and sirtuins (SIRTs) are important epigenetic regulators of cancer pathways. There is a limited understanding of how transcriptional regulation of their genes is affected by chemotherapeutic agents, and how such t
Externí odkaz:
https://doaj.org/article/76cdf0bfff0e453b87e8b5bd10e9b649
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration.
Publikováno v:
PLoS Medicine, Vol 9, Iss 5, p e1001216 (2012)
The REMARK (Reporting Recommendations for Tumor Marker Prognostic Studies) guideline includes a checklist which aims to improve the reporting of these types of studies. Here, we expand on the REMARK checklist to enhance its use and effectiveness thro
Externí odkaz:
https://doaj.org/article/81e548a8be3d485992c1d71d5cee349b
Autor:
Amy S. Clark, Fangxin Hong, Richard S. Finn, Angela M. DeMichele, Edith P. Mitchell, James Zwiebel, Fernanda I. Arnaldez, Robert J. Gray, Victoria Wang, Lisa M. McShane, Larry V. Rubinstein, David Patton, P. Mickey Williams, Stanley R. Hamilton, Mehmet S. Copur, Samer S. Kasbari, Ravneet Thind, Barbara A. Conley, Carlos L. Arteaga, Peter J. O'Dwyer, Lyndsay N. Harris, Alice P. Chen, Keith T. Flaherty
Publikováno v:
Clinical Cancer Research. 29:1477-1483
Purpose: Cyclin D/CDK4/6 is critical in controlling the G1 to S checkpoint. CCND, the gene encoding cyclin D, is known to be amplified in a variety of solid tumors. Palbociclib is an oral CDK4/6 inhibitor, approved in advanced breast cancer in combin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0deaba3a14fb4dcac6730d29e90dbb46
https://doi.org/10.1158/1078-0432.ccr-22-2150
https://doi.org/10.1158/1078-0432.ccr-22-2150
Autor:
Erich P. Huang, James P. B. O’Connor, Lisa M. McShane, Maryellen L. Giger, Philippe Lambin, Paul E. Kinahan, Eliot L. Siegel, Lalitha K. Shankar
Publikováno v:
Nature Reviews Clinical Oncology. 20(2):69-82
Computer-extracted tumour characteristics have been incorporated into medical imaging computer-aided diagnosis (CAD) algorithms for decades. With the advent of radiomics, an extension of CAD involving high-throughput computer-extracted quantitative c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::375b692ebe4292e2f74e507def2e89e0
https://doi.org/10.1038/s41571-022-00707-0
https://doi.org/10.1038/s41571-022-00707-0
Autor:
Funda Meric-Bernstam, James M. Ford, Peter J. O'Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin, Roisin E. O'Cearbhaill, Suzanne George, Julia Glade-Bender, Gary H. Lyman, James V. Tricoli, David Patton, Stanley R. Hamilton, Robert J. Gray, Douglas S. Hawkins, Bhanumati Ramineni, Keith T. Flaherty, Petros Grivas, Timothy A. Yap, Jordan Berlin, James H. Doroshow, Lyndsay N. Harris, Jeffrey A. Moscow
Publikováno v:
Clinical Cancer Research. 29:1412-1422
Over the past decade, multiple trials, including the precision medicine trial National Cancer Institute-Molecular Analysis for Therapy Choice (NCI-MATCH, EAY131, NCT02465060) have sought to determine if treating cancer based on specific genomic alter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::099b140efab4ae35818a5a0c4c867b08
https://doi.org/10.1158/1078-0432.ccr-22-3334
https://doi.org/10.1158/1078-0432.ccr-22-3334
Publikováno v:
Cancer. 128:3843-3849
Participation of adolescents and young adults (AYAs) in oncology clinical trials is important to ensure adequate opportunities for AYA patients to contribute to, and benefit from, advances in cancer treatment.Accrual data for National Cancer Institut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6688421a62e854a31ed392a7af81775a
https://doi.org/10.1002/cncr.34402
https://doi.org/10.1002/cncr.34402
Autor:
Philippe L. Bedard, Shuli Li, Kari B. Wisinski, Eddy S. Yang, Sewanti A. Limaye, Edith P. Mitchell, James A. Zwiebel, Jeffrey A. Moscow, Robert J. Gray, Victoria Wang, Lisa M. McShane, Larry V. Rubinstein, David R. Patton, P. Mickey Williams, Stanley R. Hamilton, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O'Dwyer, Alice P. Chen, Keith T. Flaherty
Publikováno v:
JCO precision oncology. 6
PURPOSE National Cancer Institute–Molecular Analysis for Therapy Choice is a multicohort trial that assigns patients with advanced cancers to targeted therapies on the basis of central tumor genomic testing. Arm B evaluated afatinib, an ErbB family
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f6bf59fabbdedba6f33eccff12578795
https://pubmed.ncbi.nlm.nih.gov/35939768
https://pubmed.ncbi.nlm.nih.gov/35939768